Prostate cancer is one of the most common cancers in men. Tumor growth is critically regulated by the androgen receptor, and treatment strategies to lower androgens, such as testosterone, are a mainstay of clinical treatment. Over time,...Show More Summary
Widespread reports of a big increase in advanced prostate cancer were based on a study whose methodology has been criticized.
The number of new cases of men suffering from metastatic prostate cancer has risen significantly in a decade's time, and is 72 percent greater in the year 2013 compared to 2004. This increase is especially worrying among men aged between...Show More Summary
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. The authors suspect the recent trend of fewer men being screened and more aggressive disease may be contributing to the rise. Show More Summary
Headlines from multiple news outlets today report that metastatic prostate cancer is “soaring,” “surging” and “skyrocketing.” The alarming headlines are based on a study that found a 72% increase in metastatic disease cases (cancers that have spread beyond the prostate) between 2004 and 2013. Show More Summary
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new study. The report considers whether a recent trend of fewer men being screened may be contributing to the rise, or whether the disease has become more aggressive -- or both. Show More Summary
For decades, experts have said the diagnostic used to screen patients for prostate cancer is too unreliable to use routinely because it produces high rates of false positives and often results in additional unnecessary and invasive tests, as well as overtreatment. Show More Summary
Highest increase among men ages 55 to 69, who could benefit the most from screening and early treatment Disease is more advanced when finally diagnosed "Screening saves lives," urologists stress. "If I were a patient, I would want to be vigilant." read more
(PHILADELPHIA) - Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options:...Show More Summary
A new tool helps remove the emotion around choosing the right approach for prostate cancer
While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary treatment, the challenge for clinicians is to monitor and distinguish early-stage tumors from advanced cancers. A team...Show More Summary
A new study is reviving hope that the approach also may help men with life-threatening prostate cancer.It is a surprising turnaround because prior results in men with aggressive, advanced-stage prostate cancer showed no evidence of anti-tumor activity with immune therapies that work by blocking PD-1 signals.
Moffitt researchers David Basanta, PhD, and Conor Lynch, PhD, have been awarded a U01 grant to investigate prostate cancer metastasis. Prostate cancer frequently spreads to the bone, and can cause painful bony lesion and increased mortality for patients. Show More Summary
A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment.
For the first time, researchers at Umeå University and Lund University have estimated the risk of developing various types of prostate cancer for men with the disease in the family. Men with brothers who have had prostate cancer run twice as high a risk of being diagnosed themselves in comparison to the general population. Show More Summary
It is a well-known fact that men with a family history of prostate cancer run an increased risk of developing the disease. The risk for brothers of men with prostate cancer is doubled. But a doubled risk of what, exactly? Prostate cancer my be an indolent condition that does not require treatment, or aggressive and fatal. Show More Summary
Genetic testing in men with advanced prostate cancer could pick up a significant proportion whose disease may be caused by inherited mutations in genes involved in repairing DNA damage, a major new study reveals. Testing prostate cancer...Show More Summary
Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred...Show More Summary
A new relationship between mutations in specific DNA repair genes and metastatic prostate cancer is found. A new approach to treatment may be on the cards.
A high-priced prostate cancer drug discovered at UCLA is at the center of a multibillion-dollar takeover battle that has several giant pharmaceutical firms eyeing the purchase of San Francisco biotech firm Medivation. Medivation sells the drug Xtandi for about $129,000 a year. Earlier this year, two...